Evercore ISI analysts upgraded CRISPR Therapeutics stock from an In Line to an Outperform rating and increased the price target significantly to $99 from the previous $60. The upgrade comes as ...

Mark Mahaney, Evercore ISI Head of Internet Research, joins 'Closing Bell Overtime' to talk Airbnb and Roku earnings.

Five-star-rated analyst Mark Mahaney at Evercore ISI has downgraded his rating from Buy to Hold on The Trade Desk (TTD) after ...

Rich Ross, head of technical analysis at Evercore ISI, said that a breakout to an all-time high in the S&P 500 ( SP500 ), ( ...

Wall Street investment bank Evercore ISI (EVR) is pounding the table on Nvidia (NVDA) stock ahead of the chipmaker’s upcoming ...

Confluent (NASDAQ:CFLT – Get Free Report) had its target price upped by Evercore ISI from $32.00 to $40.00 in a report ...

Zillow Group (NASDAQ:ZG – Get Free Report) had its target price boosted by equities research analysts at Evercore ISI from $75.00 to $90.00 in a research report issued on Wednesday,Benzinga reports.

VillageMD, the health care clinic chain backed by Walgreens Boots Alliance Inc., is working with Evercore Inc. for assistance ...

Nvidia (NASDAQ:NVDA) was added to Evercore ISI's Tactical Outperform list on Monday as analysts turned bullish ahead of the company's fiscal fourth-quarter earnings report on February 26.

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.

Investing.com -- The recent sell-off in Nvidia (NASDAQ: NVDA) stock, triggered by concerns over Chinese startup DeepSeek’s ...

Walgreens Chief Executive Officer Tim Wentworth reiterated on an earnings call last month that the company plans to divest ...